Skip to main content
NCBI home page
Proceedings of the National Academy of Sciences of the United States of America logoLink to Proceedings of the National Academy of Sciences of the United States of America
. 1991 Nov 15;88(22):10287–10291. doi: 10.1073/pnas.88.22.10287

Relative differences in the binding free energies of human immunodeficiency virus 1 protease inhibitors: a thermodynamic cycle-perturbation approach.

M R Reddy 1, V N Viswanadhan 1, J N Weinstein 1
PMCID: PMC52913  PMID: 1946447

Abstract

Peptidomimetic inhibitors of the human immunodeficiency virus 1 protease show considerable promise for treatment of AIDS. We have, therefore, been seeking computer-assisted drug design methods to aid in the systematic design of such inhibitors from a lead compound. Here we report thermodynamic cycle-perturbation calculations (using molecular dynamics simulations) to compute the relative difference in free energy of binding that results when one entire residue (valine) is deleted from one such inhibitor. In particular, we studied the "alchemic" mutation of the inhibitor Ac-Ser-Leu-Asn-(Phe-Hea-Pro)-Ile-Val-OMe (S1) to Ac-Ser-Leu-Asn-(Phe-Hea-Pro)-Ile-OMe (S2), where Hea is hydroxyethylamine, in two different (R and S) diastereomeric configurations of the hydroxyethylene group. The calculated (averaged for R and S) difference in binding free energy [3.3 +/- 1.1 kcal/mol (mean +/- SD); 1 cal = 4.184 J] is in good agreement with the experimental value of 3.8 +/- 1.3 kcal/mol, obtained from the measured Ki values for an equilibrium mixture of R and S configurations. Precise testing of our predictions will be possible when binding data become available for the two disastereomers separately. The observed binding preference for S1 is explained by the stronger ligand-protein interaction, which dominates an opposing contribution arising from the large desolvation penalty of S1 relative to S2. This calculation suggests that the thermodynamic cycle-perturbation approach can be useful even when a relatively large change in the ligand is simulated and supports the use of the thermodynamic cycle-perturbation algorithm for screening proposed derivatives of a lead inhibitor/drug prior to their synthesis.

Full text

PDF
10287

Images in this article

10289Image
on p.10289

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Beveridge D. L., DiCapua F. M. Free energy via molecular simulation: applications to chemical and biomolecular systems. Annu Rev Biophys Biophys Chem. 1989;18:431–492. doi: 10.1146/annurev.bb.18.060189.002243. [DOI] [PubMed] [Google Scholar]
  2. Davies D. R. The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem. 1990;19:189–215. doi: 10.1146/annurev.bb.19.060190.001201. [DOI] [PubMed] [Google Scholar]
  3. Erickson J., Neidhart D. J., VanDrie J., Kempf D. J., Wang X. C., Norbeck D. W., Plattner J. J., Rittenhouse J. W., Turon M., Wideburg N. Design, activity, and 2.8 A crystal structure of a C2 symmetric inhibitor complexed to HIV-1 protease. Science. 1990 Aug 3;249(4968):527–533. doi: 10.1126/science.2200122. [DOI] [PubMed] [Google Scholar]
  4. Fleischman S. H., Brooks C. L., 3rd Protein-drug interactions: characterization of inhibitor binding in complexes of DHFR with trimethoprim and related derivatives. Proteins. 1990;7(1):52–61. doi: 10.1002/prot.340070106. [DOI] [PubMed] [Google Scholar]
  5. Gao J., Kuczera K., Tidor B., Karplus M. Hidden thermodynamics of mutant proteins: a molecular dynamics analysis. Science. 1989 Jun 2;244(4908):1069–1072. doi: 10.1126/science.2727695. [DOI] [PubMed] [Google Scholar]
  6. Harte W. E., Jr, Swaminathan S., Mansuri M. M., Martin J. C., Rosenberg I. E., Beveridge D. L. Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. Proc Natl Acad Sci U S A. 1990 Nov;87(22):8864–8868. doi: 10.1073/pnas.87.22.8864. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hruby V. J., al-Obeidi F., Kazmierski W. Emerging approaches in the molecular design of receptor-selective peptide ligands: conformational, topographical and dynamic considerations. Biochem J. 1990 Jun 1;268(2):249–262. doi: 10.1042/bj2680249. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Miller M., Schneider J., Sathyanarayana B. K., Toth M. V., Marshall G. R., Clawson L., Selk L., Kent S. B., Wlodawer A. Structure of complex of synthetic HIV-1 protease with a substrate-based inhibitor at 2.3 A resolution. Science. 1989 Dec 1;246(4934):1149–1152. doi: 10.1126/science.2686029. [DOI] [PubMed] [Google Scholar]
  9. Navia M. A., Fitzgerald P. M., McKeever B. M., Leu C. T., Heimbach J. C., Herber W. K., Sigal I. S., Darke P. L., Springer J. P. Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature. 1989 Feb 16;337(6208):615–620. doi: 10.1038/337615a0. [DOI] [PubMed] [Google Scholar]
  10. Novotny J., Bruccoleri R. E., Saul F. A. On the attribution of binding energy in antigen-antibody complexes McPC 603, D1.3, and HyHEL-5. Biochemistry. 1989 May 30;28(11):4735–4749. doi: 10.1021/bi00437a034. [DOI] [PubMed] [Google Scholar]
  11. Rich D. H., Green J., Toth M. V., Marshall G. R., Kent S. B. Hydroxyethylamine analogues of the p17/p24 substrate cleavage site are tight-binding inhibitors of HIV protease. J Med Chem. 1990 May;33(5):1285–1288. doi: 10.1021/jm00167a003. [DOI] [PubMed] [Google Scholar]
  12. Rich D. H., Sun C. Q., Vara Prasad J. V., Pathiasseril A., Toth M. V., Marshall G. R., Clare M., Mueller R. A., Houseman K. Effect of hydroxyl group configuration in hydroxyethylamine dipeptide isosteres on HIV protease inhibition. Evidence for multiple binding modes. J Med Chem. 1991 Mar;34(3):1222–1225. doi: 10.1021/jm00107a049. [DOI] [PubMed] [Google Scholar]
  13. Singh U. C., Benkovic S. J. A free-energy perturbation study of the binding of methotrexate to mutants of dihydrofolate reductase. Proc Natl Acad Sci U S A. 1988 Dec;85(24):9519–9523. doi: 10.1073/pnas.85.24.9519. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Wlodawer A., Miller M., Jaskólski M., Sathyanarayana B. K., Baldwin E., Weber I. T., Selk L. M., Clawson L., Schneider J., Kent S. B. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science. 1989 Aug 11;245(4918):616–621. doi: 10.1126/science.2548279. [DOI] [PubMed] [Google Scholar]
  15. Wolfenden R., Andersson L., Cullis P. M., Southgate C. C. Affinities of amino acid side chains for solvent water. Biochemistry. 1981 Feb 17;20(4):849–855. doi: 10.1021/bi00507a030. [DOI] [PubMed] [Google Scholar]

Articles from Proceedings of the National Academy of Sciences of the United States of America are provided here courtesy of National Academy of Sciences

RESOURCES